Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non- Hodgkin's lymphoma patients

Experimental Hematology

Volumn 28, Issue 5, 2000, Pages 499-507

  Singh, Rakesh K ^a   Varney, Michelle L ^a   Ino, Kazuhiko ^a   Vose, Julie M ^a   Bierman, Philip J ^a   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cytokines; Gene expression; Immune reconstitution; NHL; Stem cell transplantation

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOGENETICS; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034018324     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00145-4     Document Type: Article

References (61)

1. Kessinger A., Armitage J.O. The evolving role of autologous peripheral stem cell transplantation following high dose therapy for malignancies. Blood. 77:1991;211.
2. Kessinger A. Is blood or bone marrow better? Stem Cells. 11:1993;290.
3. Kessinger A. Circulating stem cells. waxing hematopoietic N Engl J Med. 333:1995;315.
4. Vose J.M., Anderson J.R., Kessinger A.et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Onol. 11:1993;1846.
5. Porter D., Antin J.H. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 30:1999;369.
6. Rahman Z., Kavanagh J., Champlin R.et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 4:1998;2717.
7. Kessinger A. Re-establishing hematopoiesis after dose-intensive therapy with peripheral stem cells. In. J Armitage, K Antman (eds) High dose cancer therapy Baltimore: Williams and Wilkins. 102:1992.
8. Janssen W.E., Smilee R.C., Elfenbein G.J. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother. 4:1995;139.
9. Henon P.R., Liang H., Beck W.G.et al. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother. 4:1995;139.
10. To L.B., Roberts M.M., Haylock D.N.et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 9:1992;277.
11. Harousseau J.L., Attal M., Divine M.et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant. 15:1995;963.
12. Autran B., Malphettes M., Dhedin N., Gorochov G., Leblond V., Debre P. Studies of T cell reconstitution after hematopoietic stem cell transplant. Hematol Cell Ther. 39:1997;252.
13. Shenoy S., Mohanakumar T., Todd G.et al. Immune reconstitution following allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant. 4:1999;335.
14. Nolte A., Buhmann R., Straka C., Emmerich B., Hallek M. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 21:1998;909.
15. Rosillo M.C., Ortuno F., Moraleda J.M.et al. Immune recovery after autologous or rhG-CSF primed PBSC transplantation. Eur J Haematol. 56:1996;301.
16. Talmadge J.E. The combination of stem cell transplantation and immunotherapy. future potential In Vivo. 8:1994;675.
17. Mills K.C., Gross T.G., Varney M.L.et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant. 18:1996;53.
18. Weaver C.H., Longin K., Buckner C.D., Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 13:1994;411.
19. Talmadge J.E., Reed E.C., Kessinger A.et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant. 17:1996;101.
20. Talmadge J.E., Reed E., Ino K.et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 19:1997;161.
21. Roberts M.M., To L.B., Gillis D.et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant. 12:1993;469.
22. Singh R.K., Varney M.L., Buyukberber S.et al. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell. Cancer Res. 59:1999;3107.
23. Mielcarek M., Graf L., Johnson G., Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products. a mechanism for monocyte-mediated suppression of T-cell proliferation Blood. 92:1998;215.
24. Singh R.K., Ino K., Varney M., Heimann D., Talmadge J.E. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transplant. 23:1999;53.
25. Varney M., Ino K., Ageitos A.G., Heimann D., Talmadge J.E., Singh R.K. Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products. a mechanism of immune dysfunction J Interferon Cytokine Res. 19:2000;351.
26. Ino K., Singh R.K., Talmadge J.E. Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol. 61:1997;583.
27. Romagnani S. Human TH1 and TH2 subsets. regulation of differentiation and role in protection and immunopathology Int Arch Allergy Immunol. 98:1992;279.
28. Romagnani S. Human TH1 and TH2 subsets. doubt no more Immunol Today. 12:1991;256.
29. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241.
30. Romagnani S. Type 1 T helper and type 2 T helper cells. functions, regulation and role in protection and disease Int J Clin Lab Res. 21:1991;152.
31. Lederer J.A., Liou J.S., Todd M.D., Glimcher L.H., Lichtman A.H. Regulation of cytokine gene expression in T helper cell subsets. J Immunol. 152:1994;77.
32. Spagnoli G.C., Juretic A., Schultz T.E.et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol. 146:1993;391.
33. Yamamura M., Modlin R.L., Ohmen J.D., Moy R.L. Local expression of antiinflammatory cytokines in cancer. J Clin Invest. 91:1993;1005.
34. Kharkevitch D.D., Seito D., Balch G.C., Maeda T., Balch C.M., Itoh K. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer. 58:1994;317.
35. Nathan C.F. Secretory products of macrophages. J Clin Invest. 79:1987;319.
36. Chomczynski P., Sacchi N. Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156.
37. Welte K., Ciobanu N., Moore M.A.S., Gulati S., O'Reilly R.J., Mertelsmann R. Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood. 64:1984;380.
38. Schneider L.C., Antin J.H., Weinstein H.et al. Lymphokine profile in bone marrow transplant recipients. Blood. 78:1991;3076.
39. Lum L.G., Joshi I.D., Smith M.R.et al. Constitutive and mitogen-stimulated cytokine mRNA expression by peripheral blood mononuclear cells from most autologous and allogeneic bone marrow transplant recipients is intact. Bone Marrow Transplant. 13:1994;187.
40. Hanenberg H., Dilloo D., Laws H.-J., Zessack N., Heyll A., Burdach S. Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies. Exp Hematol. 23:1995;1543.
41. Cayeux S., Meuer S., Pezzutto A.et al. T cell ontogeny after autologous bone marrow tranplantation. failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3- mediated proliferation by both CD4+ and CD8+ cells even in the presence of exogenous IL-2 Blood. 74:1989;2270.
42. Baker K., Roncarolo M.-G., Peters C., Bigler M., DeFor T., Blazar B. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant. 23:1999;1123.
43. Asano T., Fujimaki W., McWatters A., An T., Matsushima K., Kleinerman E.S. Effect of adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother. 37:1993;408.
44. Lee L.F., Schuerer M.C., Lofquist A.K.et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 56:1996;1303.
45. Maeurer M.J., Martin D.M., Castelli C.et al. Host immune response in renal cell cancer. interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes Cancer Immunol Immunother. 41:1995;111.
46. Aguilar S.M., Loftenius A., Ljungh C.et al. Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis. Leuk Res. 16:1992;607.
47. Zeng D., Dejbakhsh J.S., Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease. impact on blood progenitor cell transplantation Blood. 90:1997;453.
48. Pan L., Delmonte J. Jr., Jalonen C.K., Ferrara J.L.M. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 86:1995;4422.
49. Kawano Y., Takaue Y., Saito S.-I.et al. Granulocyte colony stimulating factor (G-CSF), macrophage-CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood. 81:1993;856.
50. Cairo M.S., Gillan E.R., Weinthal J.et al. Decreased endogenous circulating steel factor (SLF) levels following allogeneic and autologous BMT. lack of an inverse correlation with post-BMT myeloid engraftment Bone Marrow Transplant. 11:1993;155.
51. Miksits K., Beyer J., Siegert W. Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue. Bone Marrow Transplant. 11:1993;375.
52. Haas R., Gericke G., Witt B., Caycux S., Hunstein W. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol. 21:1993;109.
53. Ho A.D., Maruyama M., Maghazachi A., Mason J.R., Gluck S., Corringham R.E.T. Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood. 84:1994;3550.
54. Guillaume T., Sekhavat M., Rubinstein D.B., Hamdan O., Leblanc P., Symann M.L. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res. 54:1994;3800.
55. Testa U., Martucci R., Rutella S.et al. Autologous stem cell transplantation. release of early and late acting growth factors relates with hematopoietic ablation and recovery Blood. 84:1994;3532.
56. Takamatsu Y., Akashi K., Harada M.et al. Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. Br J Haematol. 83:1993;21.
57. Watts M.J., Jones H.M., Sullivan A.M.et al. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol. 91:1995;767.
58. Baiocchi G.P., Scambia G., Benedetti G.et al. Autologous stem cell transplantation. Sequential production of hematopoietic cytokines underlying granulocyte recover Cancer Res. 53:1993;1297.
59. Coventry B.J., Weeks S.C., Heckford S.E., Sykes P.J., Bradley J., Skinner J.M. Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma. selective expression of early activation markers J Immunol. 156:1996;3486.
60. Garcia S.J., Lenig D. Translational control of interleukin 2 messenger RNA as a molecular mechanism of T cell anergy. J Exp Med. 184:1996;159.
61. Tanaka J., Mielcarek M., Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood. 91:1998;347.